SG11202103812RA - Exosome-targeting bispecific antibodies - Google Patents

Exosome-targeting bispecific antibodies

Info

Publication number
SG11202103812RA
SG11202103812RA SG11202103812RA SG11202103812RA SG11202103812RA SG 11202103812R A SG11202103812R A SG 11202103812RA SG 11202103812R A SG11202103812R A SG 11202103812RA SG 11202103812R A SG11202103812R A SG 11202103812RA SG 11202103812R A SG11202103812R A SG 11202103812RA
Authority
SG
Singapore
Prior art keywords
exosome
bispecific antibodies
targeting bispecific
targeting
antibodies
Prior art date
Application number
SG11202103812RA
Other languages
English (en)
Inventor
Matthew K Robinson
Michael John Morin
Original Assignee
Immunome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunome Inc filed Critical Immunome Inc
Publication of SG11202103812RA publication Critical patent/SG11202103812RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202103812RA 2018-10-17 2019-10-17 Exosome-targeting bispecific antibodies SG11202103812RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862746862P 2018-10-17 2018-10-17
PCT/US2019/056698 WO2020081786A1 (en) 2018-10-17 2019-10-17 Exosome-targeting bispecific antibodies

Publications (1)

Publication Number Publication Date
SG11202103812RA true SG11202103812RA (en) 2021-05-28

Family

ID=70284767

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103812RA SG11202103812RA (en) 2018-10-17 2019-10-17 Exosome-targeting bispecific antibodies

Country Status (12)

Country Link
US (1) US20210347895A1 (https=)
EP (1) EP3866851A4 (https=)
JP (2) JP7496818B2 (https=)
KR (1) KR20210091714A (https=)
CN (1) CN113423425A (https=)
AU (1) AU2019359877A1 (https=)
BR (1) BR112021007469A2 (https=)
CA (1) CA3116560A1 (https=)
IL (1) IL282355A (https=)
MX (1) MX2021004036A (https=)
SG (1) SG11202103812RA (https=)
WO (1) WO2020081786A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022501062A (ja) 2018-10-02 2022-01-06 イムノーム、インコーポレイテッド Ｅｐｎ１を標的とする抗体
CN113754771A (zh) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗pdl1×egfr的双特异性抗体
CN114354913B (zh) * 2021-12-31 2024-07-19 厦门大学 一种外泌体pd-l1糖基化检测方法
CN114990129B (zh) * 2022-05-11 2023-02-03 北京贝来生物科技有限公司 表达αPDL1:Fc融合蛋白的间充质干细胞的制备及应用
WO2023225613A2 (en) * 2022-05-18 2023-11-23 Immunome, Inc. Combination anti-epn1 and anti-pd-l1 antibody therapies
EP4630966A2 (en) * 2022-12-09 2025-10-15 The Regents of the University of California Intelligent design and engineering of proteins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3255060A1 (en) * 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
US20160145355A1 (en) * 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
EP4141032B1 (en) * 2014-11-20 2024-05-29 F. Hoffmann-La Roche AG Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
GB201500319D0 (en) * 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
RU2018105846A (ru) * 2015-07-29 2019-08-28 Новартис Аг Комбинация антагониста pd-1 с ингибитором egfr
WO2017087280A1 (en) * 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
US11421028B2 (en) * 2016-02-06 2022-08-23 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
PT3433273T (pt) * 2016-03-25 2022-02-21 Biomunex Pharmaceuticals Moléculas de ligação a cd38 e pd-l1
CN108250302A (zh) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多功能蛋白质

Also Published As

Publication number Publication date
CA3116560A1 (en) 2020-04-23
CN113423425A (zh) 2021-09-21
AU2019359877A1 (en) 2021-05-20
JP7496818B2 (ja) 2024-06-07
EP3866851A1 (en) 2021-08-25
US20210347895A1 (en) 2021-11-11
EP3866851A4 (en) 2022-11-02
IL282355A (en) 2021-05-31
KR20210091714A (ko) 2021-07-22
JP2024123004A (ja) 2024-09-10
BR112021007469A2 (pt) 2021-08-10
WO2020081786A1 (en) 2020-04-23
JP2022512734A (ja) 2022-02-07
MX2021004036A (es) 2021-08-24

Similar Documents

Publication Publication Date Title
IL279235A (en) DLL3-CD3 bispecific antibodies
IL280780A (en) Anti-TIGIT antibodies
IL280013A (en) Anti-IL36R antibodies
ZA202004908B (en) Bispecific antibody
IL279352A (en) IL-11RA antibodies
PL3519437T3 (pl) Przeciwciała dwuswoiste przeciwko p95HER2
GB201710838D0 (en) Bispecific antibodies
IL278010A (en) Antibodies to galectin 10
IL282756A (en) Humanized antibodies against SIRPα
SG11202106171WA (en) Anti-btla antibodies
IL277030A (en) Antibodies
SG11202007735TA (en) Anti-her2 antibodies
IL282355A (en) Bispecific antibodies directed to exosomes
ZA202101177B (en) Anti-btla antibody
IL286757A (en) Antibodies in specific
EP3693013A4 (en) BISPECIFIC ANTIBODY
GB201811368D0 (en) Antibody
IL269577B (en) Bispecific antibodies anti–pd–l1–anti–tim–3
IL286918A (en) Bispecific antibody
SG11202102114UA (en) Anti-klrg1 antibodies
ZA202206008B (en) Bispecific anti-ccl2 antibodies
IL290050A (en) Bispecific antibody
GB201911211D0 (en) Monoclonal antibodies against ambra-1
GB201806084D0 (en) Antibodies
PT3802598T (pt) Proteínas de ligação dll3/cd3 para tratamento de cancro